A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation

Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([131I]mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/CD147, was closely related to HCC invasion and metastasis. Here, we reported a randomized controlled trial to assess the post‐OLT antirecurrence efficacy of Licartin in advanced HCC patients. We randomized 60 post‐OLT patients with HCC, who were at tumor stage 3/4 and outside the Milan criteria before OLT, into 2 groups. Three weeks after OLT, the treatment group received 15.4 MBq/kg of Licartin, while the control group received placebo intravenously for 3 times with an interval of 28 days. At 1‐year follow‐up, the recurrence rate significantly decreased by 30.4% (P = 0.0174) and the survival rate increased by 20.6% (P = 0.0289) in the treatment group, compared with those in the control group. For the control group versus the treatment group, the hazard ratio for recurrence was 3.60 (95% confidence interval [CI], 1.50‐8.60) and that for death was 3.87 (95% CI, 1.23–12.21). Licartin treatment also resulted in an earlier decreased AFP level and a longer time of normal AFP level than placebo (P = 0.0016). No Licartin‐related toxic effects were observed. Conclusion: Licartin is a promising drug for preventing post‐OLT tumor recurrence in advanced HCC patients excluded by the currently strict criteria for OLT. HAb18G/CD147 can be a good drug target. (HEPATOLOGY 2007;45:269–276.)

[1]  M. Yu,et al.  HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains , 2004, Cellular and Molecular Life Sciences CMLS.

[2]  J. Wong,et al.  Recovery of malignant tumor cells from the right atrium during hepatic resection for hepatocellular carcinoma , 1983, Cancer.

[3]  Min Zhang,et al.  Biodistribution and localization of iodine-131 labeled metuximab in patients with hepatocellular carcinoma , 2006, Cancer Biology & Therapy.

[4]  D. V. van Thiel,et al.  The 11 ‐year pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981‐1991 , 1993, Journal of surgical oncology. Supplement.

[5]  S. Kar,et al.  Detection of liver cells in peripheral blood of patients with advanced‐stage hepatocellular carcinoma , 1995, Hepatology.

[6]  B. Toole.  Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. , 2003, Current topics in developmental biology.

[7]  Jing Xu,et al.  Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. , 2006, International journal of radiation oncology, biology, physics.

[8]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[9]  T. Vogl,et al.  Recurrence‐free survival after liver transplantation for small hepatocellular carcinoma , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  J. Llovet,et al.  How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? , 2005, Journal of hepatology.

[11]  M. Honda,et al.  Ephrin-A1 expression contributes to the malignant characteristics of α-fetoprotein producing hepatocellular carcinoma , 2005, Gut.

[12]  J. Geschwind,et al.  The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Davern,et al.  Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention‐to‐treat principle and dropout from the waiting list , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  Q. Ye,et al.  A decade’s studies on metastasis of hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[15]  T. Davern,et al.  A follow‐up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  I. Sheen,et al.  Does the Presence of Circulating Hepatocellular Carcinoma Cells Indicate a Risk of Recurrence after Resection? , 2004, American Journal of Gastroenterology.

[17]  Y. Liu.  [Localization of hepatocellular carcinoma with monoclonal antibodies]. , 1991, Zhonghua yi xue za zhi.

[18]  J. Fung,et al.  The quandary over liver transplantation for hepatocellular carcinoma: The greater sin? , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  J. Xu,et al.  CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients , 2006, Cancer biology & therapy.

[20]  H. Chan,et al.  The Involvement of HAb18G/CD147 in Regulation of Store-operated Calcium Entry and Metastasis of Human Hepatoma Cells* , 2001, The Journal of Biological Chemistry.

[21]  S. Mather,et al.  High efficiency iodination of monoclonal antibodies for radiotherapy. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  D. V. van Thiel,et al.  Hepatic resection versus transplantation for hepatocellular carcinoma. , 1991, Annals of surgery.

[23]  P. Waldenberger,et al.  Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[25]  G. Gores,et al.  Drop‐out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[27]  J. Xu,et al.  Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma , 2007, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[28]  K. Dou,et al.  HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. , 2005, European journal of cell biology.

[29]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[30]  A. Reid,et al.  Tumor marker for metastasis: Searching for an abnormal needle in a haystack , 1994, Hepatology.

[31]  Z. Chen.  [Significance and application of anti-malignant hepatoma MAb HAb18 in radioimmunal diagnosis of human hepatocellular carcinoma]. , 1992, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[32]  I. Penn.  Hepatic transplantation for primary and metastatic cancers of the liver. , 1991, Surgery.

[33]  M. Gnant,et al.  Does Additional Doxorubicin Chemotherapy Improve Outcome in Patients with Hepatocellular Carcinoma Treated by Liver Transplantation? , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  S. Hirohashi,et al.  Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. , 2004, The Keio journal of medicine.